Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

T Cells Engineered For Resistance To Mycophenolate Mofetil Demonstrate Enhanced Expansion and Improved Tumour Control In Immunosuppressed Hosts

James Edward Griffin, MD, Shoa-An Xue, Benjamin J Carpenter, Pedro Velica, PhD, Angelika Holler, Sara Ghorashian, MD, Emma Nicholson, MD, Martin Pule, MD, Ronjon Chakraverty, MD, PhD

Blood (2013) 122 (21): 4486.

https://doi.org/10.1182/blood.V122.21.4486.4486

Published: 2013

Journal Articles

In Vivo Selection of Mycophenolate Mofetil-Resistant T Cells for Adoptive Immunotherapy.

James Edward Griffin, MD, Ben Carpenter, MD, Emma Nicholson, MD, Shao-an Xue, PhD, Martin Pule, MD, Hans Stauss, MD, PhD, Ronjon Chakraverty, MD, PhD

Blood (2012) 120 (21): 3008.

https://doi.org/10.1182/blood.V120.21.3008.3008

Published: 2012

Journal Articles

Targeting Therapeutic T Cells to Tumour Niches.

Ben Carpenter, MD, Sara Ghorashian, MD, Emma Nicholson, MD, James Edward Griffin, MD, Maryam Ahmadi, PhD, Angelika Holler, Barry Flutter, PhD, Noha Edwards, Hans Stauss, MD, PhD, Emma Morris, MD, PhD, Ronjon Chakraverty, MD, PhD

Blood (2012) 120 (21): 3009.

https://doi.org/10.1182/blood.V120.21.3009.3009

Published: 2012

Journal Articles

Endogenous T Cell Receptors Drive Non-Specific Suppression by Foxp3 MHC Class I-Restricted T Cell Receptor-Transduced Polyclonal CD4+ T Cells in Models of Graft-Versus-Host Disease.

Benjamin J Uttenthal, MD, Emma Nicholson, MD, Ben Carpenter, MD, Sara Ghorashian, MD, Graham P Wright, PhD, Barry R Flutter, PhD, Shao-An Xue, PhD, Ronjon Chakraverty, MD, PhD, Emma Morris, MD, PhD

Blood (2012) 120 (21): 3152.

https://doi.org/10.1182/blood.V120.21.3152.3152

Published: 2012

Journal Articles

CD4 Cells Engineered to Express an MHC Class I Restricted TCR Can Rescue CD8 Cells Tolerized to Tumour-Associated Antigens

Sara Ghorashian, MD, Ben Carpenter, MD, Angelika Holler, Emma Nicholson, MD, Maryam Ahmadi, PhD, Mathias Zech, MD, Clare Bennett, PhD, Shao-An Xue, PhD, Emma Morris, MD, PhD, Hans Stauss, MD, PhD, Ronjon Chakraverty, MD, PhD

Blood (2012) 120 (21): 952.

https://doi.org/10.1182/blood.V120.21.952.952

Published: 2012

NARROW

T Cells Engineered For Resistance To Mycophenolate Mofetil Demonstrate Enhanced Expansion and Improved Tumour Control In Immunosuppressed Hosts

In Vivo Selection of Mycophenolate Mofetil-Resistant T Cells for Adoptive Immunotherapy.

Targeting Therapeutic T Cells to Tumour Niches.

Endogenous T Cell Receptors Drive Non-Specific Suppression by Foxp3 MHC Class I-Restricted T Cell Receptor-Transduced Polyclonal CD4+ T Cells in Models of Graft-Versus-Host Disease.

CD4 Cells Engineered to Express an MHC Class I Restricted TCR Can Rescue CD8 Cells Tolerized to Tumour-Associated Antigens

Email alerts

ASH Publications

American Society of Hematology

T Cells Engineered For Resistance To Mycophenolate Mofetil Demonstrate Enhanced Expansion and Improved Tumour Control In Immunosuppressed Hosts

In Vivo Selection of Mycophenolate Mofetil-Resistant T Cells for Adoptive Immunotherapy.

Targeting Therapeutic T Cells to Tumour Niches.

Endogenous T Cell Receptors Drive Non-Specific Suppression by Foxp3 MHC Class I-Restricted T Cell Receptor-Transduced Polyclonal CD4+ T Cells in Models of Graft-Versus-Host Disease.

CD4 Cells Engineered to Express an MHC Class I Restricted TCR Can Rescue CD8 Cells Tolerized to Tumour-Associated Antigens

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only